AlphaLISA<sup>®</sup> Factor VIII (Human) Biotin-Free Detection Kit

revvity

**Product number:** AL362HV/C/F

Research Use Only. Not for use in diagnostic procedures.

# Product Information

- **Application:** This kit is designed for the quantitative determination of Human Factor VIII in cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps). The kit utilizes a Digoxigenin (DIG)/ Anti-DIG interaction as opposed to the traditional Streptavidin/Biotin interaction. This enables optimal performance when working with biotin-rich media (e.g. RPMI) or samples containing endogenous biotin (e.g. milk, brain extracts).
- Sensitivity: Lower Detection Limit (LDL): 71.2 pg/mL Lower Limit of Quantification (LLOQ): 232 pg/mL EC50: 94.5 ng/mL 71.2 - 300 000 pg/mL (Figure 1).

Dynamic range:




Figure 1. Typical sensitivity curves in AlphaLISA Immunoassay Buffer. The data was generated using a white Optiplate<sup>™</sup>-384 microplate and the EnVision<sup>®</sup> Multilabel Plate Reader with Alpha option 2103.

Storage: Store kit in the dark at +4°C. Store reconstituted analyte at -20°C.

Stability: This product is stable for at least 12 months from the manufacturing date when stored in its original packaging and the recommended storage conditions.

## **Analyte of Interest**

Factor VIII is a blood clotting protein which is also called anti-hemophilic factor (AHF). Factor VIII is produced in the liver and in the endothelial cells of other organs and tissues. It circulates in the bloodstream as an inactive form complexed with von Willebrand factor (vWF). In damaged blood vessels Factor VIII disassociates from vWF to become active Factor VIII. Activated Factor VIII initiates the cascade of chemical reactions to promote blood clotting at the site of vessel damage to prevent blood loss from the body. For this reason, it has been used as a blood clotting drug for patients with hemophilia to restore hemostasis. The present kit detects hFactor VIII in human serum, plasma, cell culture supernatants, and cell lysate, and tissue homogenates.

#### **Description of the AlphaLISA Assay**

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In this AlphaLISA assay, a DIG-labeled Anti-Analyte Antibody binds to the anti-DIG Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm (Figure 2).




Figure 2. AlphaLISA Assay principle.

## **Precautions**

- Anti-Digoxigenin Fab Fragment Donor beads are light-sensitive. All the other assay reagents can be used under normal light conditions. All Alpha assays using the Donor beads should be performed under subdued laboratory lighting (< 100 lux). Green filters (LEE 090 filters (preferred) or Roscolux filters #389 from Rosco) can be applied to light fixtures.
- All blood components and biological materials should be handled as potentially hazardous. The analyte included in this kit is from a Mouse source.
- Some analytes are present in saliva. Take precautionary measures to avoid contamination of the reagent solutions.
- The DIG labeled anti-analyte antibody is toxic. Contact with skin or inhalation should be avoided.

# **Kit Content: Reagents and Materials**

Kit components	AL362HV (100 assay points***)	AL362C (500 assay points***)	AL362F (5000 assay points***)
AlphaLISA Anti-hFactor VIII Acceptor beads stored in PBS, 0.05% Kathon, pH 7.2	20 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	50 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	500 µL @ 5 mg/mL (1 brown tube, <u>white</u> cap)
Anti-Digoxigenin Fab Fragment Donor beads stored in 25 mM HEPES, 100 mM NaCl, 0.05% Kathon, pH 7.4	80 μL @ 5 mg/mL (1 brown tube, <u>black</u> cap)	200 µL @ 5 mg/mL (1 brown tube, <u>black</u> cap)	2 X 1 mL @ 5 mg/mL (2 brown tubes, <u>black</u> caps)
DIG labeled Anti-hFactor VIII stored in PBS, 0.1% Tween- 20, 0.05% NaN <sub>3</sub> , pH 7.4	20 µL @ 500 nM (1 tube, <u>black</u> cap)	50 μL @ 500 nM (1 tube, <u>black</u> cap)	500 μL @ 500 nM (1 tube, <u>black</u> cap)
AlphaLISA hFactor VIII (0.3 µg), lyophilized Analyte *	0.3 μg; lyophilized solid (1 tube, <u>clear</u> cap)	0.3 μg; lyophilized solid (1 tube, <u>clear</u> cap)	0.3 μg; lyophilized solid (1 tube, <u>clear</u> cap)
AlphaLISA Immunoassay Buffer (10X)**	2 mL, 1 small bottle	10 mL, 1 medium bottle	100 mL, 1 large bottle

Reconstitute human FACTOR VIII in 100  $\mu$ L Milli-Q<sup>®</sup> grade H<sub>2</sub>O. The reconstituted analyte should be used within 60 minutes or aliquoted into screw-capped polypropylene vials and stored at 4°C for further experiments. Avoid multiple freeze-thaw cycles. It has been demonstrated that reconstituted human FACTOR VIII is stable for at least 75 days at -20°C. One vial contains an amount of human FACTOR VIII sufficient for performing 10 standard curves. Additional vials can be ordered separately (cat # AL342S).

Extra buffer can be ordered separately (cat # AL000C: 10 mL, cat # AL000F: 100 mL).

The number of assay points is based on an assay volume of 100  $\mu$ L in 96-well plates or 50  $\mu$ L in 96- or 384-well assay plates using the kit components at the recommended concentrations.

Sodium azide should **not** be added to the stock reagents. High concentrations of sodium azide (> 0.001 % final in the assay) might decrease the AlphaLISA signal.

#### Specific additional required reagents and materials:

The following materials are recommended:

ltem	Suggested source	Catalog #
TopSeal <sup>™</sup> -A Plus Adhesive Sealing Film	Revvity Inc.	6050185
EnVision <sup>®</sup> -Alpha Reader	Revvity Inc.	-

## Recommendations

- The volume indicated on each tube is guaranteed for single pipetting. Multiple pipetting of the reagents may reduce the theoretical amount left in the tube. To minimize loss when pipetting beads, it is preferable not to pre-wet the tip.
- Centrifuge all tubes (including lyophilized analyte) before use to improve recovery of content (2000g, 10-15 sec). Re-suspend all reagents by vortexing before use.
- Use Milli-Q<sup>®</sup> grade H<sub>2</sub>O (18 MΩ•cm) to dilute 10X AlphaLISA Immunoassay Buffer to reconstitute the lyophilized analyte.
- When diluting the standard or samples, <u>change tips</u> between each standard or sample dilution. When loading
  reagents in the assay microplate, <u>change tips</u> between each standard or sample addition and after each set
  of reagents.
- When reagents are added to the microplate, make sure the liquids are at the bottom of the well.
- Small volumes may be prone to evaporation. It is recommended to cover microplates with TopSeal-A Adhesive Sealing Films to reduce evaporation during incubation. Microplates can be read with the TopSeal-A Film.
- The AlphaLISA signal is detected with an EnVision Multilabel Reader equipped with the Alpha option using the AlphaScreen standard settings (e.g. Total Measurement Time: 550 ms, Laser 680 nm Excitation Time: 180 ms, Mirror: D640as, Emission Filter: M570w, Center Wavelength 570 nm, Bandwidth 100 nm, Transmittance 75%).
- AlphaLISA signal will vary with temperature and incubation time. For consistent results, identical incubation times and temperature should be used for each plate.
- The standard curves shown in this technical data sheet are provided for information only. A standard curve must be generated for each experiment. The standard curve should be performed in the Immunoassay buffer for serum and/or plasma samples.

## Assay Procedure

IMPORTANT: PLEASE READ THE RECOMMENDATIONS BELOW BEFORE USE

- The manual described below is an example for generating one standard curve in a 50 µL final assay volume (48 wells, triplicate determinations). The manuals also include testing samples in 452 wells. If a different amount of samples are tested, <u>the volumes of all reagents have to be adjusted accordingly</u>, as shown in the <u>table below</u>. These calculations do not include excess reagent to account for losses during transfer of solutions or dead volumes.
- The standard dilution manual is provided for information only. As needed, the number of replicates or the range of concentrations covered can be modified.
- Use of four background points in triplicate (12 wells) is recommended when LDL/LLOQ is calculated. One background point in triplicate (3 wells) can be used when LDL/LLOQ is not calculated.

		Volume					
Format	# of data points	Final	Sample	Acceptor Beads	DIG- Antibody	Donor beads	Plate recommendation
AL362HV	100	100 µL	10 µL	20 µL	20 µL	50 µL	White OptiPlate-96 (cat # 6005290) White ½ AreaPlate-96 (cat # 6005560)
	250	100 µL	10 µL	20 µL	20 µL	50 µL	White OptiPlate-96 (cat # 6005290) White ½ AreaPlate-96 (cat # 6005560)
AL362C	500	50 µL	5 µL	10 µL	10 µL	25 µL	White ½ AreaPlate-96 (cat # 6005560) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate <sup>™</sup> -384 (cat # 6005350)
	1 250	20 µL	2 µL	4 µL	4 µL	10 µL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate <sup>™</sup> -384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	2 500	10 µL	1 µL	2 µL	2 µL	5 µL	Light gray AlphaPlate-1536 (cat # 6004350)
	5 000	50 µL	5 µL	10 µL	10 µL	25 µL	White ½ AreaPlate-96 (cat # 6005560) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate-384 (cat # 6005350)
AL362F	12 500	20 µL	2 µL	4 µL	4 µL	10 µL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	25 000	10 µL	1 µL	2 µL	2 µL	5 μL	Light gray AlphaPlate-1536 (cat # 6004350)

## High Sensitivity 3-step Manual for hFactor VIII AlphaLISA Assay

## The manual described below is for one standard curve (48 wells).

If a different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly.

1) Preparation of 1X AlphaLISA Immunoassay Buffer:

Add 10 mL of 10X AlphaLISA Immunoassay Buffer to 90 mL H<sub>2</sub>O.


- 2) Preparation of hFactor VIII analyte standard dilutions:
  - a) <u>Reconstitute</u> lyophilized hFactor VIII (0.3  $\mu$ g) in 100  $\mu$ L of H<sub>2</sub>O.
  - b) <u>Prepare</u> standard dilutions as follows in 1X AlphaLISA Immunoassay Buffer (change tip between each standard dilution):

Tube	Vol. of	Vol. of	[hFactor VIII ] in standard curve		
Tube	Tube hFactor VIII (μL)		(g/mL in 5 μL)	(pg/mL in 5 µL)	
A	10 μL of provided hFactor VIII	90	3.00E-07	300 000	
В	60 µL of tube A	120	1.00E-07	100 000	
С	60 μL of tube B	140	3.00E-08	30 000	
D	60 µL of tube C	120	1.00E-08	10 000	
E	60 µL of tube D	140	3.00E-09	3 000	
F	60 μL of tube E	120	1.00E-09	1 000	
G	60 µL of tube F	140	3.00E-10	300	
Н	60 μL of tube G	120	1.00E-10	100	
I	60 µL of tube H	140	3.00E-11	30	
J	60 μL of tube I	120	1.00E-11	10	
K	60 μL of tube J	140	3.00E-12	3	
L	60 μL of tube K	120	1.00E-12	1	
M ** (background)	0	100	0	0	
N ** (background)	0	100	0	0	
O ** (background)	0	100	0	0	
P ** (background)	0	100	0	0	

Dilute standards in diluent (e.g. 1X AlphaLISA Immunoassay Buffer).
 At low concentrations of analyte, a significant amount of analyte can bind to the vial. Therefore, load the analyte standard dilutions in the assay microplate within 60 minutes of preparation.

- \*\* Four background points in triplicate (12 wells) are used when LDL is calculated. If LDL does not need to be calculated, one background point in triplicate can be used (3 wells).
- 3) Preparation of 5X AlphaLISA Anti-hFactor VIII Antibody Acceptor beads (50 µg/mL):
  - a. Add 50 μL of 5 mg/mL AlphaLISA Anti-hFactor VIII Antibody Acceptor to 4950 μL of 1X AlphaLISA Immunoassay Buffer.
  - b. Prepare just before use.
- 4) Preparation of 5X DIG labeled Anti-hFactor VIII Antibody (5 nM):
  - a. Add 50 µL of 500 nM DIG labeled Anti-hFactor VIII Antibody to 4950 µL of 1X AlphaLISA Immunoassay Buffer.
  - b. Prepare just before use.
- 5) Preparation of 2X Anti-Digoxigenin Fab Fragment Donor beads (80 µg/mL):
  - a. Keep the beads under subdued laboratory lighting.
  - b. Add 200 μL of 5 mg/mL Anti-Digoxigenin Fab Fragment Donor beads to 12300 μL of 1X AlphaLISA Immunoassay Buffer.
  - c. Prepare just before use.

#### 6) In a white Optiplate (384 wells):



# **Data Analysis**

- Calculate the average count value for the background wells.
- Generate a standard curve by plotting the AlphaLISA counts versus the concentration of analyte. A log scale can be used for either or both axes. No additional data transformation is required.
- Analyze data according to a nonlinear regression using the 4-parameter logistic equation (sigmoidal dose-response curve with variable slope) and a 1/Y<sup>2</sup> data weighting (the values at maximal concentrations of analyte after the hook point should be removed for correct analysis).
- The LDL is calculated by interpolating the average background counts (12 wells without analyte) + 3x standard deviation value (average background counts + (3xSD)) on the standard curve.
- The LLOQ as measured here is calculated by interpolating the average background counts (12 wells without analyte) + 10 x standard deviation value (average background counts + (10xSD)) on the standard curve. Alternatively, the true LLOQ can be determined by spiking known concentrations of analyte in the matrix and measuring the percent recovery, and then determining the minimal amount of spiked analyte that can be quantified within a given limit (usually +/- 20% or 30% of the real concentration).
- Read from the standard curve the concentration of analyte contained in the samples.
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.


# **Assay Performance Characteristics**

AlphaLISA assay performance described below was determined using the High Sensitivity 3 step manual.

Assay Sensitivity:

The LDL was calculated as described in the data analysis section. The values correspond to the lowest concentration of analyte that can be detected using the recommended assay conditions.

LDL (pg/mL)	Buffer/Media	# of experiments
71.2	Immunoassay Buffer	9
113.2	RPMI with 10% FBS	8



- Note that LDL can be decreased (i.e. sensitivity increased) by increasing the volume of analyte in the assay (e.g. use 10 μL of analyte in a final assay volume of 50 μL).
  - <u>Assay Precision:</u>

The following assay precision data were calculated from the three independent assays using two different kit lots. In each lot, the analytes were prepared in AlphaLISA Immunoassay Buffer, or RPMI. Each assay consisted of one standard curve comprising 12 data points (each in triplicate) and 12 background wells (no analytes). The assays were performed in 384-well format using AlphaLISA Immunoassay Buffer.

#### Intra-assay precision:

The intra-assay precision was determined using 3 independent experiments for a total of 16 independent determinations in triplicate. CV% were calculated for each individual experiment then averaged. Shown is the average intra-experimental CV%.

hFactor VIII	Immunoassay Buffer	RPMI
CV%	5%	7%

#### • Inter-assay precision:

The inter-assay precision was determined using the data across 3 independent experiments with 16 measurements in triplicate. CV% was calculated by comparing the same measurement in each experiment. The CV% for all 16 measurements was then averaged. Shown is the inter-experimental CV%.

hFactor VIII	Immunoassay Buffer	RPMI
CV%	15%	12%

#### • Spike Recovery:


Four known concentrations of analyte were spiked in AlphaLISA Immunoassay Buffer and cell culture media supplemented with 10% FBS. The spiked samples were referenced to the analyte curve produced in AlphaLISA Immunoassay Buffer and culture media.

Spiked	% Recovery	
hFactor VIII (ng/mL)	Immunoassay Buffer	RPMI
30	95	92
10	87	85
3	95	88
1	97	90

# **Troubleshooting Guide**

You will find detailed recommendations for common situations you might encounter with your AlphaLISA Assay kit at: <u>www.revvity.com</u>

#### RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF

www.revvity.com

revvity

Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA www.revvity.com

For a complete listing of our global offices, visit www.revvity.com Copyright ©2023, Revvity, Inc. All rights reserved.